Current Issues of Pharmacy and Medical Sciences

Contemporary pharmacological obesity treatments

Curr Issues Pharm Med Sci., Vol. 29, No. 2, 57-60

Katarzyna Kaszubska, Barbara Budzynska, Grazyna Biala

Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, 4a Chodzki, 20-093 Lublin, Poland


DOI: 10.1515/cipms-2016-0012

Abstract

In the last few years, obesity has become a global epidemic. Consequently, worldwide costs associated with managing obesity and obesity-related comorbidities are huge. Numerous studies have focused on discerning the appropriate proper treatment of weight related problems such as overweight and obesity. Moreover, many clinical trials have been conducted for many years in order to introduce effective anti-obesity drugs. The aim of the present review is to provide an overview of current and future pharmacotherapy for obesity, and to provide the reader with a determination of the concentration and composition of long and short term anti-obesity drugs, doing so by placing emphasis on pharmacotherapy and up-to-day solutions. It should be noted that, currently, the worldwide pharmacotherapy is represented by phendimetrazine, benzphetamine and diethylpropion, as well as by orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion and liraglutide. In our paper, individual cases of patients’ needs are thoroughly illustrated by way of examples. Medical prescriptions and contraindications are also described.

 

FULL TEXT

Keywords

pharmacotherapy, obesity, Body Mass Index, drug.

Calendar

July 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31